The influence of age on aerosol deposition in children with cystic fibrosis

Nebulized aerosols are commonly used to deliver drugs for the treatment of respiratory disease in children, but there are inadequate data on the dose of drug depositing in the lungs in this age group, and the effect of age on this dose. We therefore aimed to quantify total and regional deposition of nebulized aerosol in children of widely differing age. Twelve infants (median age 0.8 yrs, range 0.3-1.4 yrs) who were asleep, and eight older children (median age 10.8 yrs, range 6.3-18.0 yrs) with cystic fibrosis were studied. Radiolabelled normal saline aerosol was generated by a Turret nebulizer, with a driving flow of 9 l.min-1. All subjects inhaled aerosol via the nasal route, whilst the older children undertook a second study with inhalation via the oral route. Following aerosol inhalation, planar and single-photon emission computed tomography (SPECT) scans were obtained. For the nasal route, total lung deposition was lower in infants (median 1.3%, range 0.3-1.6%) than in older children (median 2.7%, range 1.6-4.4%). For the older children inhaling via the nasal or oral route, there was no influence of age on lung, upper respiratory tract, or the sum of upper respiratory tract and lung deposition. We conclude that the dose of a nasally inspired aerosol reaching the lungs of infants who are asleep is approximately half that for older children, when the nebulizer is operating at 9 l.min-1. Age does not affect deposition of nasally or orally inspired aerosols in older children.

This article has been cited by other articles:

				A. Becker, C. Lemiere, D. Berube, L.-P. Boulet, F. M. Ducharme, M. FitzGerald, T. Kovesi, and on behalf of The Asthma Guidelines Working Group o Summary of recommendations from the Canadian Asthma Consensus Guidelines, 2003 Can. Med. Assoc. J., September 13, 2005; 173(6_suppl): S3 - S11. [Full Text] [PDF]

				Inhalation devices Can. Med. Assoc. J., September 13, 2005; 173(6_suppl): S39 - S45. [Full Text] [PDF]

				G. A. Alothman, B. Ho, M. M. Alsaadi, S. L. Ho, L. O'Drowsky, E. Louca, and A. L. Coates Bronchial Constriction and Inhaled Colistin in Cystic Fibrosis Chest, February 1, 2005; 127(2): 522 - 529. [Abstract] [Full Text] [PDF]

				M L Everard Ethical aspects of using radiolabelling in aerosol research Arch. Dis. Child., August 1, 2003; 88(8): 659 - 661. [Full Text] [PDF]

				H. M. Janssens, J. C. de Jongste, W. C. J. Hop, and H. A. W. M. Tiddens Extra-Fine Particles Improve Lung Delivery of Inhaled Steroids in Infants: A Study in an Upper Airway Model Chest, June 1, 2003; 123(6): 2083 - 2088. [Abstract] [Full Text] [PDF]

				I. Amirav, I. Balanov, M. Gorenberg, A. S. Luder, M. T. Newhouse, and D. Groshar {beta}-Agonist Aerosol Distribution in Respiratory Syncytial Virus Bronchiolitis in Infants J. Nucl. Med., April 1, 2002; 43(4): 487 - 491. [Abstract] [Full Text] [PDF]

				T. R. Flotte and B. L. Laube Gene Therapy in Cystic Fibrosis Chest, September 1, 2001; 120 (2009): 124S - 131S. [Abstract] [Full Text] [PDF]

				A. L. Coates, P. D. Allen, C. F. MacNeish, S. L. Ho, and L. C. Lands Effect of Size and Disease on Estimated Deposition of Drugs Administered Using Jet Nebulization in Children With Cystic Fibrosis Chest, April 1, 2001; 119(4): 1123 - 1130. [Abstract] [Full Text] [PDF]

				B. FAUROUX, E. ITTI, J. PIGEOT, D. ISABEY, M. MEIGNAN, G. FERRY, F. LOFASO, J.-M. WILLEMOT, A. CLÉMENT, and A. HARF Optimization of Aerosol Deposition by Pressure Support in Children with Cystic Fibrosis . An Experimental and Clinical Study Am. J. Respir. Crit. Care Med., December 1, 2000; 162(6): 2265 - 2271. [Abstract] [Full Text]

				J. A. ØJ, L. THORSSON, and H. BISGAARD Lung Deposition of Inhaled Drugs Increases with Age Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1819 - 1822. [Abstract] [Full Text]

				Inhalation devices and propellants Can. Med. Assoc. J., November 1, 1999; 161(90111): s44 - 50. [Full Text]

				R Iles, P Lister, and A T Edmunds Crying significantly reduces absorption of aerosolised drug in infants Arch. Dis. Child., August 1, 1999; 81(2): 163 - 165. [Abstract] [Full Text]

				D. Wilson, M. Burniston, E. Moya, A. Parkin, S. Smye, P. Robinson, and J. Littlewood Improvement of nebulised antibiotic delivery in cystic fibrosis Arch. Dis. Child., April 1, 1999; 80(4): 348 - 352. [Abstract] [Full Text]

				L Agertoft, A Andersen, E Weibull, and S Pedersen Systemic availability and pharmacokinetics of nebulised budesonide in preschool children Arch. Dis. Child., March 1, 1999; 80(3): 241 - 247. [Abstract] [Full Text]